+44 (0) 20 7079 4399
Call HCA from 8am-8pm Mon-Fri and 9am-5pm Sat
HCA Healthcare UK
Dr Sarah Blagden
Gynaecological cancers (chemotherapy)
Dr Sarah Blagden is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust, the Ovarian Cancer Action Research Centre. She specialises in the treatment of gynaecological cancers, such as ovarian cancer and is the director of the Phase I cancer trials unit at Hammersmith Hospital. Dr Blagden's research work covers the molecular biology of chemotherapy resistance in ovarian cancer. In addition, she has conducted research into the ongoing survivorship needs of ovarian cancer patients and has an ongoing interest in this area.
To Make an appointment, call HCA on +44(0)20 7079 4399
or click here
Call the contact centre
+44 (0) 20 7079 4399
8am-8pm Mon-Fri, 9am-5pm Sat
Let us call you backCan we call you back at a more convenient time
Email contact centreSend us an email and we will get back to you.
© copyright 2008 - 2017 HCA Healthcare UK.
Registered Name: HCA International Limited; The part of the UK in which it is registered: England and Wales;
Registered Number: 03020522; Registered Office Address: 242 Marylebone Road London NW1 6JL.
£500m has been invested by HCA International in the latest medical technologies and facilities over the last 10 years.
Your hospital will be one of our world-class private hospitals: HCA’s world-class hospitals are accredited by The CHKS Accreditation Unit, a leading provider of healthcare intelligence and quality improvement services. The accreditation is a measure of the overall quality of a hospital and hospitals with CHKS accreditation have been shown to provide a better quality of service.
Your safety will be protected because we have more critical care beds than any other private hospital group: HCA hospitals achieved 100% compliance with all Care Quality Commission inspected outcomes of care in 2011.
Your treatment will be undertaken using the most advanced diagnostic and treatment facilities: Oliver Wyman, Corporate Accounts: Driving quality and value, January 2012.